Defining Baseline Recurrence Risk in Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor–Negative Early Breast Cancer: A Meta-Analysis of Endocrine Therapy Arms From Phase 3 Trials, Including the CDK4/6 Inhibitor Era
Purpose Patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) early breast cancer (EBC) are at risk of invasive recurrence despite standard endocrine therapy (ET). Prior meta-analyses largely reflect historical, lower-risk populations and may not capture recurrence patterns in contemporary, high-risk cohorts. This systematic literature review and meta-analysis evaluated risk of recurrence or death (ROR) with adjuvant ET ± chemotherapy across phase 3 randomized controlled trials (RCTs) from the past 2 decades, including recent cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) trials enrolling high-risk populations. Methods The search identified 19 phase 3 RCTs (2003–2024) reporting invasive disease-free survival/disease-free survival in patients with HR+/HER2 − EBC treated with ET ± chemotherapy. Pooled recurrence proportions at 3, 4, 5, 7, and 12 years were estimated using random-effects meta-analysis of proportions. Kaplan-Meier digitization analysis and meta-analysis among tumor characteristics and trial date subgroups were conducted. Results Nineteen RCTs (34 publications; >47,000 patients) met inclusion criteria. Among stage I-III patients receiving ET ± chemotherapy, pooled invasive ROR was 13% at 5 years and 27% at 12 years. At 4 years, ROR was 18% in stage II/III, 15% in node-positive, 11% in high-risk node-negative, and 7% in all-node-negative patients. Reconstructed survival curves showed a relatively constant hazard rate of ≈ 2%-3% per year through 12 years. Conclusions Phase 3 trials spanning aromatase inhibitor to CDK4/6i eras demonstrated substantial invasive ROR that emerged early and persisted through 12 years despite ET ± chemotherapy, underscoring the need for improved risk stratification and therapeutic strategy optimization beyond standard ET.
Authors
- Giuseppe Curigliano (ORCID: https://orcid.org/0000-0003-1781-2518)
- Peter Andreas Fasching (ORCID: https://orcid.org/0000-0003-4885-8471)
- Dave Nellesen
- Paolo Tarantino (ORCID: https://orcid.org/0000-0001-8686-0228)
- Olivia Shane
- D Proudman
- Vaidyanathan Ganapathy
- Adrienne Kwok
- Eva Ciruelos
- Yen-Shen Lu
- Erika Hamilton
- Kevin Kalinsky
- Corinth Auld
- Nick McAndrew
Institutions
- Harvard University (US)
- Emory University (US)
- University of California, Los Angeles (US)
- Sarah Cannon Research Institute (GB)
- Universitätsklinikum Erlangen (DE)
- Novartis (United States) (US)
- National Taiwan University Hospital (TW)
- Solti (ES)
- Comprehensive Cancer Center Erlangen (DE)
- European Institute of Oncology (IT)
- Analysis Group (United States) (US)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-20
- DOI
- https://doi.org/10.21203/rs.3.rs-11434843/v1
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- preprint
Funders
- Novartis Pharmaceuticals Corporation